Last Updated: August 9, 2026

CLINICAL TRIALS PROFILE FOR OTEZLA XR

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for OTEZLA XR

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Amgen	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Celgene Corporation	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00773734 ↗	Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)	Completed	Amgen	Phase 2	2008-09-01	The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00773734 ↗	Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)	Completed	Celgene Corporation	Phase 2	2008-09-01	The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for OTEZLA XR

Condition Name

Chart
Table

Condition Name for OTEZLA XR
Intervention	Trials
Psoriasis	11
Plaque Psoriasis	10
Psoriatic Arthritis	6
Behcet Syndrome	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for OTEZLA XR
Intervention	Trials
Psoriasis	27
Arthritis	9
Arthritis, Psoriatic	8
Dermatitis	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for OTEZLA XR

Trials by Country

Map
Table

Trials by Country for OTEZLA XR
Location	Trials
United States	267
Canada	49
Australia	15
Germany	15
Japan	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for OTEZLA XR
Location	Trials
California	19
Florida	16
New York	15
Texas	13
Illinois	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for OTEZLA XR

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for OTEZLA XR
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	17
Phase 3	13
[disabled in preview]	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for OTEZLA XR
Clinical Trial Phase	Trials
Completed	21
Recruiting	14
Not yet recruiting	4
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OTEZLA XR

Sponsor Name

Chart
Table

Sponsor Name for OTEZLA XR
Sponsor	Trials
Amgen	23
Celgene Corporation	19
Celgene	9
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for OTEZLA XR
Sponsor	Trials
Industry	56
Other	52
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.